Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880).
about
Membrane transport of camptothecin: facilitation by human P-glycoprotein (ABCB1) and multidrug resistance protein 2 (ABCC2)Antiviral action of camptothecinExploring DNA topoisomerase I ligand space in search of novel anticancer agentsPhase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT)Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x 5 intravenous administrationThe bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitorA phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion.Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I.Perspectives on biologically active camptothecin derivatives.Synergistic antitumor activity of camptothecin-doxorubicin combinations and their conjugates with hyaluronic acid.Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development.A phase I study with MAG-camptothecin intravenously administered weekly for 3 weeks in a 4-week cycle in adult patients with solid tumoursCancer therapies utilizing the camptothecins: a review of the in vivo literatureAnti-tumour activity and toxicity of the new prodrug 9-aminocamptothecin glucuronide (9ACG) in miceRibosome formation is blocked by camptothecin, a reversible inhibitor of RNA synthesis.Semisynthesis, cytotoxic activity, and oral availability of new lipophilic 9-substituted camptothecin derivatives.Mixed PEG-PE/vitamin E tumor-targeted immunomicelles as carriers for poorly soluble anti-cancer drugs: improved drug solubilization and enhanced in vitro cytotoxicity.Topoisomerase I inhibitors and drug resistanceIdentification and characterization of a deletion mutant of DNA topoisomerase I mRNA in a camptothecin-resistant subline of human colon carcinoma.Necrotic Effect versus Apoptotic Nature of Camptothecin in Human Cervical Cancer Cells.Plastic surgery: treatment of melanoma.CPT-11 may provide therapeutic efficacy for esophageal squamous cell cancer and the effects correlate with the level of DNA topoisomerase I protein.A pharmacokinetic and pharmacodynamic analysis of CPT-11 and its active metabolite SN-38.Pharmacological correlation between total drug concentration and lactones of CPT-11 and SN-38 in patients treated with CPT-11.Topoisomerases as anticancer targets.A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo.DNA damage and cell killing by camptothecin and its derivative in human leukemia HL-60 cells.
P2860
Q24799793-EF3EFE91-AD9E-4F87-9756-6E7220915C91Q28363163-FFCE3F18-6670-4A6F-BBCD-51012DF8929FQ28477194-B77FC5A5-C2BD-41EF-9D60-92A64FE3301AQ33361186-D3C37C68-BEF0-4B00-AF59-1238A5F74AFDQ33495553-7E0FFE33-8FBF-4EAB-BFF9-614194BB4C9DQ33500497-1F3A2AFE-59E3-4AD8-8A34-0775720E4B73Q33504409-4E5BB412-C0F7-4965-BD5C-F093C53E5373Q34336896-B376D4D1-8345-43D5-A814-21C999F323FAQ34468628-C636ACAB-A2FE-40C6-BCB8-C7BD0E1EA724Q35751958-61F093FF-CFAD-4C3A-85F2-E5C22763D881Q36431807-CA37AA92-0BC9-4CE6-B2E7-32E88A3C8F3BQ36694292-3483EBED-DFC8-44C5-AF34-315C2FC73A66Q37069556-FAB1F146-82E2-47F7-91A4-FBBED1F40D54Q37352745-CEF7BB86-CB77-4F4B-BB4A-B054F53BE0A1Q37493717-4964C27E-7B93-4BD0-876A-D6F3AF98457AQ39777927-EF5E023D-0899-4C5E-9AF5-78B4ED486D7BQ39967885-CE387BA0-F89E-4A7E-A35D-C8BFE8B07DE8Q40028536-DEE40AA9-49E9-42B1-91D8-B72AC8B22126Q40876335-EF3715DB-E27F-40C5-8360-99E4D8B0E946Q41787096-41636D1F-AF59-49EA-8E0E-F6752BDF9603Q42542806-4B66A1C9-C19F-4D48-8CBB-62158A8F85A0Q43827787-C5605023-3A34-48DE-AE52-D71A6A7F0C3EQ49164024-C51E43B1-EA73-41FE-8E3F-3A0CBEC71378Q49164031-AE380D93-486C-40D1-BCFE-14AC19D9A1FEQ49832269-68C4D04A-1F23-4303-A2D3-DFA2AACE85A2Q54167076-5CE41791-06EA-434E-8BCF-F9950FD363ACQ54966041-A2D9A6D2-97BA-44AD-B522-DEA73145434C
P2860
Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880).
description
1970 nî lūn-bûn
@nan
1970 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1970 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1970年の論文
@ja
1970年論文
@yue
1970年論文
@zh-hant
1970年論文
@zh-hk
1970年論文
@zh-mo
1970年論文
@zh-tw
1970年论文
@wuu
name
Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880).
@ast
Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880).
@en
type
label
Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880).
@ast
Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880).
@en
prefLabel
Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880).
@ast
Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880).
@en
P2093
P1476
Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880).
@en
P2093
A M Guarino
J A Gottlieb
V T Oliverio
P304
P577
1970-12-01T00:00:00Z